Neutralizing antibodies are known to have a crucial role in protecting against SARS-CoV-2
infection and have been suggested to be a useful correlate of protection for vaccine clinical …

Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

Seasonal influenza vaccines offer little protection against pandemic influenza virus strains. It
is difficult to create effective prepandemic vaccines because it is uncertain which influenza …

Antibody-dependent enhancement (ADE) is a mechanism by which the pathogenesis of
certain viral infections is enhanced in the presence of sub-neutralizing or cross-reactive non …

Broadly neutralizing antibodies that target epitopes of haemagglutinin on the influenza virus
have the potential to provide near universal protection against influenza virus infection …

Antibodies play an essential role in host defence against pathogens by recognizing
microorganisms or infected cells. Although preventing pathogen entry is one potential …

Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections
and hospitalization in infants under 1 year of age and there is currently no market-approved …

Neuraminidase is one of the two surface glycoproteins of influenza A and B viruses. It has
enzymatic activity that cleaves terminal sialic acid from glycans, and that activity is essential …

Influenza A virions possess two surface glycoproteins—the hemagglutinin (HA) and
neuraminidase (NA)—which exert opposite functions. HA attaches virions to cells by binding …

Oncolytic viruses (OVs) represent a new class of cancer immunotherapeutics. Administration
of OVs to cancer-bearing hosts induces two distinct immunities: antiviral and antitumor …